Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug development in metabolic dysfunction-associated steatohepatitis (MASH).

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab at the 98th Congress of the German Society of Neurology in Berlin. The ...